舒泰神(300204.SZ):香塘集團及其一致行動人的累計減持比例超5%
格隆匯5月30日丨舒泰神(300204.SZ)公佈,公司於2021年5月28日收到持股5%以上股東香塘集團有限公司(“香塘集團”)及其一致行動人出具的《簡式權益變動報吿書》,2019年3月27日至2021年5月27日,香塘集團及其一致行動人通過深圳證券交易所集中競價交易系統及大宗交易系統對外累計減持公司無限售條件流通股股份2490.8344萬股,減持比例為5.30%;因期間有表決權股份總數(即總股本剔除回購專户股份數量)發生變動,香塘集團及其一致行動人被動增持0.12%,因此,香塘集團及一致行動人累計減持比例為5.18%。累計減持比例達到公司總持股數量的5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.